Skip to main content

Advertisement

Open Peer Review Reports for: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
7 Oct 2015 Submitted Original manuscript
7 Nov 2015 Reviewed Reviewer Report - Yusuke Okuma
8 Nov 2015 Reviewed Reviewer Report - Chang-Hsien Lu
8 Dec 2015 Author responded Author comments - Victor Lee
Resubmission - Version 2
8 Dec 2015 Submitted Manuscript version 2
22 Jan 2016 Author responded Author comments - Victor Lee
Resubmission - Version 3
22 Jan 2016 Submitted Manuscript version 3
6 Feb 2016 Author responded Author comments - Victor Lee
Resubmission - Version 4
6 Feb 2016 Submitted Manuscript version 4
Publishing
17 Feb 2016 Editorially accepted
24 Feb 2016 Article published 10.1186/s12885-016-2201-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement